“We are very pleased that the XCOIL^TM Encapsulator can now be marketed together with the XCOIL^TM Retractor. The XCOIL^TM Retractor is indicated for removal of blood clots,” said John Kucharczyk, NexGen Medical Systems’ CEO. “There are more than 1,000,000 individuals in the United States that could potentially benefit from use of these XCOIL devices,” added Kucharczyk.

The indications for use of the XCOIL^TM Encapsulator are “percutaneous access to the peripheral vascular system…designed to assist in the placement and removal of devices.”

“The XCOIL^TM Encapsulator will be used in conjunction with the XCOIL^TM Retractor to remove blood clots in peripheral arteries and veins, including clots associated with deep vein thrombosis (DVT),” said Richard Latchaw, the Company’s medical director. “The XCOIL^TM Retractor deploys multiple thin coils behind and in front of blood clots. Once positioned, the coils are cinched together to firmly ensnare the clot. The XCOIL^TM System enables clots, such as often found in DVT, to be quickly and safely removed from the body,” added Latchaw.

The XCOIL^TM Retractor previously received FDA 510(k) clearance for “…removal of embolic/thrombotic material, including thrombus and debris, from peripheral arteries and veins, peripheral bypass grafts, and the removal of thrombus from dialysis grafts and arterio-venous fistulas…”

About NexGen Medical Systems

NexGen Medical Systems is a development stage company that designs medical devices that improve interventional procedures in patients with neurological and cardiovascular diseases. The Company has an office in Reno, NV, and a product development and manufacturing center in Melbourne, FL. NexGen Medical Systems is developing two medical device product lines that address urgent clinical needs in the interventional radiology and neurosurgery markets. The Company’s initial focus is on commercializing an integrated medical device product line for comprehensive management of blood clots.

Media Contact

For additional information about NexGen Medical Systems, please contact John Kucharczyk, CEO, tel. (775) 851-7337, fax (321) 728-0127, email: johnkucharczyk@nexgenmedsystem.com, web site: www.nexgenmedsystem.com

“We are pleased that the XCOIL^TM Retractor can now be marketed for removal of blood clots in patients with deep vein thrombosis (DVT)”, said John Kucharczyk, NexGen Medical Systems’ CEO.” Of the over 450,000 individuals per year in the United States who suffer from DVT, approximately 250,000 could potentially benefit from treatment with the XCOIL device. The XCOIL^TM Retractor will facilitate removal of blood clots from clogged veins and arteries in the legs and arms. Another 150,000 patients with thrombosed hemodialysis grafts could also be treated,” added Kucharczyk.

The indications for use for the XCOIL^TM Retractor are “removal of embolic / thrombotic material, including thrombus and debris, from peripheral arteries and veins, peripheral bypass grafts, and the removal of thrombus from dialysis grafts and arterio-venous fistulas”.

“The XCOIL^TM Retractor deploys multiple coils behind, throughout, and in front of blood clots,” said Richard Latchaw, the Company’s medical director. “Once positioned, the coils are then cinched together to firmly ensnare hard clot, as well as more bulky soft clot. The XCOIL^TM Retractor removes clots quickly and easily without thrombolytic drugs and without damaging venous valves,” added Latchaw.

“NexGen Medical Systems is developing medical device products to address unmet clinical needs in large patient populations, including deep vein thrombosis, peripheral arterial disease, and ischemic stroke,” Kucharczyk added. “The XCOIL^TM Retractor is another important step NexGen Medical Systems is taking to develop an integrated medical device product line for comprehensive management of blood clots.”

About NexGen Medical Systems

NexGen Medical Systems is a development stage company that designs medical devices that improve interventional procedures in patients with neurological and cardiovascular diseases. The Company has an office in Reno, NV, and a product development and manufacturing center in Melbourne, FL. NexGen Medical Systems is developing two medical device product lines that address urgent clinical needs in the interventional radiology and neurosurgery markets. The Company’s initial focus is on commercializing an integrated medical device product line for comprehensive management of blood clots.

Media Contact

For additional information about NexGen Medical Systems, please contact John Kucharczyk, CEO, tel. (775) 851-7337, fax (321) 728-0127, email: johnkucharczyk@nexgenmedsystem.com, web site: www.nexgenmedsystem.com

“We are delighted to welcome Jeff to the NexGen team,” said CEO John Kucharczyk. “He has had a long and distinguished career as a physician, and also has valuable senior management and financing experience. His expertise in technology development, intellectual property creation and venture financing will bring great value to the Company”, Kucharczyk added.

After graduating from the MBA Program in the Business of Health Program at Johns Hopkins in 2005 and retiring from the practice of Otolaryngology, Dr. Hausfeld represented three major pharmaceutical companies as their national spokesperson. In 2006, he completed a graduate certificate program at George Washington University in Leadership Coaching and Organizational Development. Dr. Hausfeld is currently one of the Managing Directors of FMS Financial Solutions, a national debt collection and debt acquisition firm specializing in medical debt collection. Over the past two years he has been working to syndicate a healthcare related real estate venture where a new entity, Memory Care Communities of Illinois LLC, will construct ten Assisted Living facilities in the Midwest specializing in the care of Alzheimer’s and dementia patients. Through the contributions of Hedge Funds and private equity investors, he has raised six million dollars in commitments. He continues to strive to achieve “Centers of Excellence” through his contacts with the Alzheimer’s Association of America as well as universities specializing in geriatrics and neurosciences. In 2011, Dr. Hausfeld became Cofounder and Treasurer of the Society of Physician Entrepreneurs, a nonprofit organization whose mission is to assist healthcare providers in commercializing their innovations through networking, education and sharing their experiences.

“Great companies are built around the integrity of their leaders, the vision of their technological applications, and the ability of the management team to accurately assess market need and successfully fill that gap. I am proud to join the Board of Directors of NexGen Medical Systems and to assist them in bringing life-changing innovations to the medical marketplace”, said Jeff Hausfeld.

About NexGen, Inc
NexGen Medical Systems is a development stage company that designs medical devices that improve the safety and efficacy of interventional procedures in patients with neurological and cardiovascular diseases. NexGen’s R&D and product development center is located in Melbourne, FL.

NexGen Medical Systems is developing three medical device products that address urgent clinical needs in the interventional radiology and neurosurgery markets. NexGen Medical Systems’ first product is a proprietary catheter-based blood clot retriever that is indicated for the removal of embolic/thrombotic material, including thrombus from peripheral blood vessels and peripheral bypass grafts, clotted synthetic dialysis grafts and arterio-venous fistulas. Initial studies in human patients have shown the XCOIL^TM Retractor to be safe, easy to use, and effective in retrieving clots from vessels in peripheral blood vessels. The Company is also adapting its platform design for peripheral arterial applications in patients with deep vein thrombosis, and for cerebrovascular thrombectomy applications in ischemic stroke patients.

NexGen Medical Systems’ second product being developed is a brain trauma device for monitoring and treating patients with acute head injury. This catheter-based device will provide combined monitoring and treatment capability not found in currently marketed devices. The Company believes that its brain trauma device will dramatically simplify treatment of acute brain injury patients by eliminating the need for implanting multiple intracranial devices.

NexGen Medical Systems’ third medical device product line is comprised of acute and chronic neurological delivery catheters. The Company’s acute delivery catheter is a proprietary medical device for drug and cell therapy of the central nervous system in patients with tumors, neurodegenerative diseases, and stroke. EViTAR-I is indicated for “the injection of material into, or the removal of material from, the brain during intracranial procedures.”

Media Contact
For additional information about NexGen Medical Systems, please contact John Kucharczyk, Chief Executive Officer, (775) 851-7337, fax (321) 728-0127, email: jkucharczyk@nexgenmedsystem.com

About NexGen, Inc

NexGen Medical Systems, Inc. is a development stage company that designs medical devices that improve the safety and efficacy of interventional procedures in patients with neurological and cardiovascular diseases. NexGen’s R&D and product development center is located in Melbourne, FL.

NexGen is developing three medical device products that address urgent clinical needs in the interventional radiology and neurosurgery markets. NexGen’s first product is a proprietary catheter-based retriever that has received FDA 510(k) clearance for peripheral arteries, peripheral bypass grafts, clotted synthetic dialysis grafts and arterio-venous fistulas. Initial studies in human patients have shown the MRD to be safe, easy to use, and effective in retrieving clots from vessels in peripheral blood vessels. The Company has adapted its platform design for peripheral arterial applications targeted at patients with peripheral atherosclerosis, for venous applications in patients with deep vein thrombosis, and for cerebrovascular thrombectomy applications in ischemic stroke patients.

Media Contacts

For additional information about NexGen, please contact John Kucharczyk, President & CEO, (775) 851-7337, jkucharczyk@nexgenmedsystem.com For additional information regarding NexGen’s investors, please contact Cary Adams, (916) 949-9863, caryadams@sbcglobal.com, or Joel Braunstein, (410) 653-9685, jbraun@ltdpartners.com

About NexGen, Inc

NexGen Medical Systems, Inc. is a development stage company that designs medical devices that improve the safety and efficacy of interventional procedures in patients with neurological and cardiovascular diseases. NexGen’s R&D and product development center is located in Melbourne, FL.

NexGen is developing three medical device products that address urgent clinical needs in the interventional radiology and neurosurgery markets. NexGen’s first product is a proprietary catheter-based retriever that has received FDA 510(k) clearance for peripheral arteries, peripheral bypass grafts, clotted synthetic dialysis grafts and arterio-venous fistulas. Initial studies in human patients have shown the MRD to be safe, easy to use, and effective in retrieving clots from vessels in peripheral blood vessels. The Company has adapted its platform design for peripheral arterial applications targeted at patients with peripheral atherosclerosis, for venous applications in patients with deep vein thrombosis, and for cerebrovascular thrombectomy applications in ischemic stroke patients.

Media Contacts

For additional information about NexGen, please contact John Kucharczyk, President & CEO, (775) 851-7337, jkucharczyk@nexgenmedsystem.com For additional information regarding NexGen’s investors, please contact Cary Adams, (916) 949-9863, caryadams@sbcglobal.com, or Joel Braunstein, (410) 653-9685, jbraun@ltdpartners.com

About NexGen, Inc

NexGen Medical Systems, Inc. is a development stage company that designs medical devices that improve the safety and efficacy of interventional procedures in patients with neurological and cardiovascular diseases. NexGen’s R&D and product development center is located in Melbourne, FL.

NexGen is developing three medical device products that address urgent clinical needs in the interventional radiology and neurosurgery markets. NexGen’s first product is a proprietary catheter-based retriever that has received FDA 510(k) clearance for peripheral arteries, peripheral bypass grafts, clotted synthetic dialysis grafts and arterio-venous fistulas. Initial studies in human patients have shown the MRD to be safe, easy to use, and effective in retrieving clots from vessels in peripheral blood vessels. The Company has adapted its platform design for peripheral arterial applications targeted at patients with peripheral atherosclerosis, for venous applications in patients with deep vein thrombosis, and for cerebrovascular thrombectomy applications in ischemic stroke patients.

Media Contacts

For additional information about NexGen, please contact John Kucharczyk, President & CEO, (775) 851-7337, jkucharczyk@nexgenmedsystem.com For additional information regarding NexGen’s investors, please contact Cary Adams, (916) 949-9863, caryadams@sbcglobal.com, or Joel Braunstein, (410) 653-9685, jbraun@ltdpartners.com

About NexGen, Inc

NexGen Medical Systems, Inc. is a development stage company that designs medical devices that improve the safety and efficacy of interventional procedures in patients with neurological and cardiovascular diseases. NexGen’s R&D and product development center is located in Melbourne, FL.

NexGen is developing three medical device products that address urgent clinical needs in the interventional radiology and neurosurgery markets. NexGen’s first product is a proprietary catheter-based retriever that has received FDA 510(k) clearance for peripheral arteries, peripheral bypass grafts, clotted synthetic dialysis grafts and arterio-venous fistulas. Initial studies in human patients have shown the MRD to be safe, easy to use, and effective in retrieving clots from vessels in peripheral blood vessels. The Company has adapted its platform design for peripheral arterial applications targeted at patients with peripheral atherosclerosis, for venous applications in patients with deep vein thrombosis, and for cerebrovascular thrombectomy applications in ischemic stroke patients.

Media Contacts

For additional information about NexGen, please contact John Kucharczyk, President & CEO, (775) 851-7337, jkucharczyk@nexgenmedsystem.com For additional information regarding NexGen’s investors, please contact Cary Adams, (916) 949-9863, caryadams@sbcglobal.com, or Joel Braunstein, (410) 653-9685, jbraun@ltdpartners.com

About NexGen, Inc

NexGen Medical Systems, Inc. is a development stage company that designs medical devices that improve the safety and efficacy of interventional procedures in patients with neurological and cardiovascular diseases. NexGen’s R&D and product development center is located in Melbourne, FL.

NexGen is developing three medical device products that address urgent clinical needs in the interventional radiology and neurosurgery markets. NexGen’s first product is a proprietary catheter-based retriever that has received FDA 510(k) clearance for peripheral arteries, peripheral bypass grafts, clotted synthetic dialysis grafts and arterio-venous fistulas. Initial studies in human patients have shown the MRD to be safe, easy to use, and effective in retrieving clots from vessels in peripheral blood vessels. The Company has adapted its platform design for peripheral arterial applications targeted at patients with peripheral atherosclerosis, for venous applications in patients with deep vein thrombosis, and for cerebrovascular thrombectomy applications in ischemic stroke patients.

Media Contacts

For additional information about NexGen, please contact John Kucharczyk, President & CEO, (775) 851-7337, jkucharczyk@nexgenmedsystem.com For additional information regarding NexGen’s investors, please contact Cary Adams, (916) 949-9863, caryadams@sbcglobal.com, or Joel Braunstein, (410) 653-9685, jbraun@ltdpartners.com

About NexGen, Inc

NexGen Medical Systems, Inc. is a development stage company that designs medical devices that improve the safety and efficacy of interventional procedures in patients with neurological and cardiovascular diseases. NexGen’s R&D and product development center is located in Melbourne, FL.

NexGen is developing three medical device products that address urgent clinical needs in the interventional radiology and neurosurgery markets. NexGen’s first product is a proprietary catheter-based retriever that has received FDA 510(k) clearance for peripheral arteries, peripheral bypass grafts, clotted synthetic dialysis grafts and arterio-venous fistulas. Initial studies in human patients have shown the MRD to be safe, easy to use, and effective in retrieving clots from vessels in peripheral blood vessels. The Company has adapted its platform design for peripheral arterial applications targeted at patients with peripheral atherosclerosis, for venous applications in patients with deep vein thrombosis, and for cerebrovascular thrombectomy applications in ischemic stroke patients.

Media Contacts

For additional information about NexGen, please contact John Kucharczyk, President & CEO, (775) 851-7337, jkucharczyk@nexgenmedsystem.com For additional information regarding NexGen’s investors, please contact Cary Adams, (916) 949-9863, caryadams@sbcglobal.com, or Joel Braunstein, (410) 653-9685, jbraun@ltdpartners.com

About NexGen, Inc

NexGen Medical Systems, Inc. is a development stage company that designs medical devices that improve the safety and efficacy of interventional procedures in patients with neurological and cardiovascular diseases. NexGen’s R&D and product development center is located in Melbourne, FL.

NexGen is developing three medical device products that address urgent clinical needs in the interventional radiology and neurosurgery markets. NexGen’s first product is a proprietary catheter-based retriever that has received FDA 510(k) clearance for peripheral arteries, peripheral bypass grafts, clotted synthetic dialysis grafts and arterio-venous fistulas. Initial studies in human patients have shown the MRD to be safe, easy to use, and effective in retrieving clots from vessels in peripheral blood vessels. The Company has adapted its platform design for peripheral arterial applications targeted at patients with peripheral atherosclerosis, for venous applications in patients with deep vein thrombosis, and for cerebrovascular thrombectomy applications in ischemic stroke patients.

Media Contacts

For additional information about NexGen, please contact John Kucharczyk, President & CEO, (775) 851-7337, jkucharczyk@nexgenmedsystem.com For additional information regarding NexGen’s investors, please contact Cary Adams, (916) 949-9863, caryadams@sbcglobal.com, or Joel Braunstein, (410) 653-9685, jbraun@ltdpartners.com